Abbott files Humira for Crohn’s
This article was originally published in Pharmaceutical Approvals Monthly
Abbott has submitted an sBLA for Humira (adalimumab) for treatment of moderate-to-severe Crohn's disease, the company announced Sept. 7. Abbott is highlighting its anti-tumor necrosis factor monoclonal antibody's dosing advantage over Johnson & Johnson's anti-TNF MAb Remicade (infliximab); Humira is injected subcutaneously every other week for Crohn's, while Remicade requires infusion. UCB's Cimzia (certolizumab pegol), a fragment of an anti-TNF MAb, is also dosed subcutaneously and is likely to be approved for Crohn's before Humira: UCB submitted a BLA Feb. 28, 2006, and is predicting launch in the first half of 2007...
You may also be interested in...
UCB’s imminent submission of Cimzia for rheumatoid arthritis slated for the end of the year is another step toward a stronger biotech presence for the company.
The Honest Company’s new digital and strategy chief joins from Amazon.com where he led development of home security systems and contactless, in-garage delivery for more than 50m Amazon Key customers. More cosmetics people news, including new supply chain and sustainability leadership at the Independent Beauty Association.
Under new user fee agreement, sponsors will get at least 60-day notice when a pre-approval inspection is necessary; regulators and manufacturers hope increased communications will lead to more efficient reviews.